您当前的位置：
首页 >
文章列表页 >
Cost-effectiveness of lecanemab for early Alzheimer disease
更新时间：2026-07-10

    • Cost-effectiveness of lecanemab for early Alzheimer disease

    • ZHONGGUO YAOFANG   Vol. 37, Issue 13, Pages: 1735-1739(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.13.13    

      CLC： R956

    • Received：18 March 2026，

      Revised：2026-06-29，

      Accepted：29 June 2026，

      Published：15 July 2026

    移动端阅览

  • XIONG Chaogang,WEI Junsong,AN Mengna,et al.Cost-effectiveness of lecanemab for early Alzheimer disease[J].ZHONGGUO YAOFANG,2026,37(13):1735-1739. DOI： 10.6039/j.issn.1001-0408.2026.13.13.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Analysis of dilemmas and recommendations for value assessment of antitumor combination therapies
Long-term clinical effectiveness and cost-effectiveness of 10 first-line antiretroviral therapy regimens for HIV-infected patients in China
Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer
Pharmacoeconomic evaluation of zolbetuximab combined with chemotherapy as first-line treatment for CLDN18.2-positive and HER2-negative advanced gastric cancer
Rapid health technology assessment of lecanemab in the treatment of early-stage Alzheimer’s disease

Related Author

WANG Xuerong
ZHOU Ting
LI Yan
LI Hongchao
ZHOU Kejia
ZHOU Dachuang
TANG Wenxi
LIU Ran

Related Institution

School of International Pharmaceutical Business， China Pharmaceutical University
Research Center for Pharmacoeconomics Evaluation， China Pharmaceutical University
Dept. of Pharmacy， Hebei Medical University Third Hospital
School of Graduate， Hebei Medical University
Hebei Society for Integrated Drug and Health Technology Assessment
0